In a filing, Marex Group Plc revealed its Officer Crispin Robert John Irvin acquired Company’s shares for reported $78694.0 on Mar 12 ’25. In the deal valued at $31.77 per share,2,477 shares were bought.
Then, Simon Van Den Born bought 26,731 shares, generating $972,474 in total proceeds.
Before that, Nilesh Kumar Jethwa bought 299,473 shares. Marex Group Plc shares valued at $9,514,257 were divested by the Officer at a price of $31.77 per share.
HSBC Securities downgraded its Marex Group Plc [MRX] rating to a Hold from a a Buy in a research note published on March 10, 2025; the price target was increased to $36 from $33. A number of analysts have revised their coverage, including HSBC Securities’s analysts, who began to cover the stock in late November with a ‘”a Buy”‘ rating. UBS started covering the stock on May 20, 2024. It rated MRX as “a Buy”.
Price Performance Review of MRX
On Tuesday, Marex Group Plc [NASDAQ:MRX] saw its stock jump 1.92% to $48.33. Over the last five days, the stock has gained 4.00%. Marex Group Plc shares have risen nearly 55.05% since the year began. Nevertheless, the stocks have risen 154.37% over the past one year. While a 52-week high of $48.91 was reached on 05/13/25, a 52-week low of $18.13 was recorded on 03/10/25. SMA at 50 days reached $38.38, while 200 days put it at $30.92.
Levels Of Support And Resistance For MRX Stock
The 24-hour chart illustrates a support level at 47.51, which if violated will result in even more drops to 46.68. On the upside, there is a resistance level at 49.25. A further resistance level may holdings at 50.16. The Relative Strength Index (RSI) on the 14-day chart is 73.31, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.32, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 10.06%. Stochastics %K at 87.22% indicates the stock is a selling.
The most recent change occurred on May 20, 2024 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $27 price target.
